Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial

Frank V. Aguirre, Eric J. Topol, Keaven M. Anderson, Neal S. Kleiman, Harlan F. Weisman, Susan E. FitzPatrick, Robert M. Califf

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial'. Together they form a unique fingerprint.